Index

Note: Page numbers of article titles are in boldface type.

A

Acute-phase proteins
  in FCoV diagnosis, 1146–1149
Aspergillosis
  in companion parrots
    transmission to dogs and cats, 1266–1268
Astroviruses (AstVs)
  causes of, 1087–1088
  described, 1087–1089
  in dogs, 1087–1095
    causes of, 1087–1088
    cultivation in vitro, 1090
    diagnosis of, 1093
    genome organization of, 1090–1091
    pathogenesis of, 1091–1092
AstVs. See Astroviruses (AstVs)
Avian influenza
  in companion parrots
    transmission to dogs and cats, 1266

B

Biochemical profile
  in FCoV diagnosis, 1146
Bordetella bronchiseptica
  FRDC due to, 1278
Brucella canis
  canine brucellosis due to, 1209
Brucellosis
  canine, 1209–1219. See also Canine brucellosis

C

Calicivirus(es)
  in cats
    FRDC due to, 1275–1277
    described, 1171–1172
    in dogs, 1172–1173
Canine brucellosis, 1209–1219
  causative agent, 1209
  clinical signs of, 1210–1211
  diagnosis of, 1212–1216
epidemiology of, 1209
prevention of, 1217–1218
reporting of, 1218
transmission of, 1210
treatment of, 1216–1217
zoonotic concerns related to, 1218
Canine coronavirus (CCoV), 1121–1132
described, 1121
evolution of, 1122–1123
genome of, 1122
origin of, 1122–1123
overview of, 1121–1123
pantropic, 1123–1129
clinical outbreaks of, 1123–1126
diagnosis of, 1128
emergence of, 1123–1126
experimental infections, 1126–1127
molecular virology of, 1127–1128
prevention of, 1128–1129
treatment of, 1128–1129
structure of, 1121–1122
taxonomy of, 1122
Canine distemper virus (CDV)
described, 1069–1070
in domestic dogs from urban wildlife, 1069–1086
diagnosis of, 1071–1072
epidemiology of, 1078–1079
genotypes of, 1073–1074
genotyping of, 1073–1074
noncanid hosts of, 1074–1075
prevention of, 1072–1073, 1075–1077
spread of, 1078
surveillance and control in U.S., 1077
vaccination for, 1072–1073
properties of, 1069–1070
Canine hepatozoonosis, 1230–1232. See also Hepatozoon spp. infections; Hepatozoonosis, canine
Canine herpesvirus (CHV)
carrier states, 1112
clinical ecology and epidemiology of, 1113–1115
clinical features of, 1097
described, 1097–1098
detection of, 1109–1112
latency sites in, 1109
molecular methods in, 1111–1112
reactivation following corticosteroid administration, 1110–1111
spontaneous reactivation in, 1109–1110
diseases due to, 1097–1120
ocular disorders, 1103–1109
reproductive disorders, 1098–1100
respiratory disorders, 1100–1103
shedding patterns in, 1112–1113
synonyms for, 1097
treatment of, 1115
Canine noroviruses (NoVs), 1171–1181. See also Norovirus(es) (NoVs), canine
Canine oral papillomatosis, 1186
Canine papillomavirus, 1183–1195. See also Papillomavirus(es) (PVs), canine
Cat(s)
  companion parrot disease transmission to, 1261–1272. See also Parrots, companion,
disease transmission to dogs and cats
  coronavirus in, 1133–1169. See also Feline coronavirus (FCoV)
  FIP in, 1133–1169. See also Feline coronavirus (FCoV); Feline infectious peritonitis
     (FIP)
  FIPV in, 1133–1169. See also Feline coronavirus (FCoV); Feline infectious peritonitis
     virus (FIPV)
  FIV in, 1197–1208. See also Feline immunodeficiency virus (FIV)
  North American snake envenomation in, 1239–1259. See also Snake envenoma-
     tion, North American, in dogs and cats
  respiratory disease complex in, 1273–1289. See also Feline respiratory disease
     complex (FRDC)
  CBC. See Complete blood count (CBC)
  CCOV. See Canine coronavirus (CCoV)
  CDV. See Canine distemper virus (CDV)
  Cell-mediated immunity
     FIPV and, 1143–1144
  Chlamydophila spp.
     C. felis
       FRDC due to, 1277–1278
     C. psittaci
       companion parrot diseases related to
transmission to dogs and cats, 1263–1264
  CHV. See Canine herpesvirus (CHV)
  Companion parrots
    disease transmission to dogs and cats, 1261–1272. See also Parrots, companion,
disease transmission to dogs and cats
  Complete blood count (CBC)
    in FCoV diagnosis, 1146
  Coronavirus(es)
    canine, 1121–1132. See also Canine coronavirus (CCoV)
genome of, 1122
    structure of, 1121–1122
taxonomy of, 1122
  Corticosteroid(s)
    CHV reactivation following administration of, 1110–1111
  Cryptococcus neoformans
    companion parrot diseases related to
transmission to dogs and cats, 1268–1269
  Cryptosporidium spp.
    companion parrot diseases related to
transmission to dogs and cats, 1270
D

Distemper
canine
in domestic dogs from urban wildlife, 1069–1086. See also Canine distemper virus (CDV), in domestic dogs from urban wildlife described, 1070

Dog(s)
astroviruses in, 1087–1095. See also Astroviruses (AstVs), in dogs
brucellosis in, 1209–1219. See also Canine brucellosis
caliciviruses in, 1172–1173
companion parrot disease transmission to, 1261–1272. See also Parrots, companion, disease transmission to dogs and cats
coronavirus in, 1121–1132. See also Canine coronavirus (CCoV) domestic
from urban wildlife
    CDV spillover in, 1069–1086. See also Canine distemper virus (CDV), in domestic dogs from urban wildlife
Hepatozoon spp. infections in, 1221–1238. See also Hepatozoon spp. infections
herpesvirus in, 1097–1120. See also Canine herpesvirus (CHV)
North American snake envenomation in, 1239–1259. See also Snake envenomation, North American, in dogs and cats
NoVs in, 1171–1181. See also Norovirus(es) (NoVs), canine
PVs in, 1183–1195. See also Papillomavirus(es) (PVs), canine

E

Effusion fluid
in FCoV diagnosis, 1149

Elapid envenomation
clinical signs of, 1243–1244

F

FCoV. See Feline coronavirus (FCoV)
Feline calicivirus
    FRDC due to, 1275–1277
Feline coronavirus (FCoV), 1133–1169
causes of, 1133–1136
common historical findings in, 1144
described, 1133
diagnosis of, 1145–1154
    acute-phase proteins in, 1146–1149
    CBC and biochemical profile in, 1146
described, 1145–1146
    effusion fluid in, 1149
    histopathology in, 1151–1153
    immunostaining in, 1154
    mRNA RT-PCR in, 1151
    RT-PCR in, 1150–1151
    serology in, 1149–1150
    serum proteins in, 1146
epidemiology of, 1136–1138
FIP due to, 1133–1169. See also Feline infectious peritonitis (FIP)
FIPV due to, 1133–1169. See also Feline infectious peritonitis virus (FIPV)
  genetics and biotype considerations in, 1134–1136
  group 1, 1134
  in multicat environments, 1133–1169
  pathology of, 1138–1144
  gross pathology, 1138–1140
  physical examination findings in, 1144–1145
  presentation of, 1144–1145
  prevalence of, 1136
  prevention of, 1155–1156
  prognosis of, 1154
  risk factors for, 1136
  shedding of, 1141–1142
  treatment of, 1154–1159. See also Feline infectious peritonitis (FIP), treatment of
  vaccination for, 1155
Feline herpesvirus-1 (FHV)
  FRDC due to, 1277
Feline immunodeficiency virus (FIV), 1197–1208
  diagnosis of, 1198–1199
  in domestic cats, 1199–1202
  in nondomestic felids, 1202–1203
  pathophysiology of, 1197
Feline infectious peritonitis (FIP)
  classification of, 1138
  diagnosis of, 1145–1154. See also Feline coronavirus (FCoV), diagnosis of
  FCoV and, 1133–1169. See also Feline coronavirus (FCoV); Feline infectious
  peritonitis virus (FIPV)
  incidence of, 1136–1138
  outbreaks of, 1138
  pathology of, 1138–1144
  FIPV and cell-mediated immunity, 1143–1144
  FIPV and humoral immunity, 1143
  FIPV and hypersensitivity, 1140–1141
  FIPV and innate immunity, 1142
  FIPV and innate immunity, 1142
  immunity and stress in shelter cats, 1144
  shedding of FCoV, 1141–1142
  prevention of, 1155–1156
  risk factors for, 1136–1138
  treatment of, 1154–1159
    after exposure, 1156
    client education in, 1159
    in multicat environments, 1156
    outbreak management, 1156–1159
Feline infectious peritonitis virus (FIPV)
  cell-mediated immunity and, 1143–1144
  FCoV and, 1133–1169. See also Feline coronavirus (FCoV); Feline infectious
  peritonitis (FIP)
  humoral immunity and, 1143
hypersensitivity and, 1140–1141
innate immunity and, 1142
Feline respiratory disease complex (FRDC), 1273–1289
  clinical presentation of, 1274
  described, 1273
  diagnosis of, 1279–1280
  pathogens of, 1275–1279
    prevalence of, 1279
  prevention of, 1282–1284
    population management in, 1283
    sanitation in, 1284
    stress reduction in, 1283
    vaccination in, 1282–1283
  treatment of, 1281–1282
FHV. See Feline herpesvirus-1 (FHV)
FIP. See Feline infectious peritonitis (FIP)
FIPV. See Feline infectious peritonitis virus (FIPV)
FIV. See Feline immunodeficiency virus (FIV)
FRDC. See Feline respiratory disease complex (FRDC)

G

Genotype(s)
  of CDV in domestic dogs from urban wildlife, 1073–1074
Giardiasis
  in companion parrots
    transmission to dogs and cats, 1270–1271

H

Hepatozoon spp. infections
  described, 1221–1222
  in U.S., 1221–1238
    clinical presentations of, 1230–1231
    diagnosis of, 1230–1231
    genetic characterization and phylogenetic relationships of, 1232–1233
    geographic distributions of, 1222
    H. americanum
      definitive tick hosts of, 1223–1225
      geographic distributions of, 1222
      prevalence of, 1222
      tissue tropism and development within canine hosts, 1227–1230
      transmission to canid intermediate hosts, 1225–1227
      wildlife reservoir hosts, 1222–1223
    H. canis
      definitive tick hosts of, 1223–1225
      geographic distributions of, 1222
      prevalence of, 1222
      tissue tropism and development within canine hosts, 1227–1230
      transmission to canid intermediate hosts, 1225–1227
      wildlife reservoir hosts, 1222–1223
prevalence of, 1222
   treatment of, 1231–1232
   wildlife reservoir hosts of, 1222–1223
Hepatozoonosis
   canine. See also Hepatozoon spp. infections
      clinical presentations of, 1230–1231
      diagnosis of, 1230–1231
      treatment of, 1231–1232
Herpesvirus
   canine, 1097–1120. See also Canine herpesvirus (CHV)
Herpesvirus-1
   feline
      FRDC due to, 1277
Histoplasmosis
   in companion parrots
      transmission to dogs and cats, 1269–1270
Humoral immunity
   FIPV and, 1143
Hypersensitivity
   FIPV and, 1140–1141

I
Immunity
   cell-mediated
      FIPV and, 1143–1144
   humoral
      FIPV and, 1143
   innate
      FIPV and, 1142
   in shelter cats, 1144
Immunodeficiency virus
   feline, 1197–1208. See also Feline immunodeficiency virus (FIV)
Immunostaining
   in FCoV diagnosis, 1154
Influenza
   avian
      in companion parrots
         transmission to dogs and cats, 1266
Influenza virus
   FRDC due to, 1278–1279
Innate immunity
   FIPV and, 1142

M
Messenger RNA (mRNA) RT-PCR
   in FCoV diagnosis, 1151
mRNA. See Messenger RNA (mRNA)
Mycobacterium spp.
   companion parrot diseases related to
      transmission to dogs and cats, 1261–1263
Mycoplasma spp.
FRDC due to, 1278

N
Norovirus(es) (NoVs)
canine, 1171–1181
causes of, 1171–1172
described, 1173
diagnosis of, 1177
genetic heterogeneity in, 1173–1174
pathologic potential of, 1174–1177
zoonotic potential of, 1177–1178
described, 1171
North America
snake envenomation in dogs and cats in, 1239–1259. See also Snake envenomation, North American, in dogs and cats
venomous snakes in, 1239–1242
NoVs. See Norovirus(es) (NoVs)

O
Ocular disorders
canine
CHV and, 1103–1109
Oral papillomatosis
canine, 1186

P
Papilloma(s)
inverted, 1186–1187
Papillomatosis
oral
canine, 1186
Papillomavirus(es) (PVs)
canine, 1183–1195
causes of, 1183–1184
clinical findings in, 1186–1188
clinical symptoms of, 1184
diagnosis of, 1188–1190
epidemiology of, 1184–1185
inverted papillomas with, 1186–1187
oral papillomatosis with, 1186
pathogenesis of, 1185–1186
pathologies related to, 1183
pigmented plaques with, 1187–1188
prevention of, 1190–1191
treatment of, 1190–1191
Parrots
companion
disease transmission to dogs and cats, 1261–1272
aspergillosis, 1266–1268
avian influenza, 1266
Chlamyphila psittaci and, 1263–1264
Cryptococcus neoformans and, 1268–1269
Cryptosporidium spp. and, 1270
Giardiasis, 1270–1271
Histoplasmosis, 1269–1270
Mycobacterium spp. and, 1261–1263
Salmonellosis, 1264–1265
Yersinia pseudotuberculosis and, 1265

Peritonitis
  feline infectious. See Feline infectious peritonitis (FIP)

Pit vipers
  envenomation by
    clinical signs of, 1244–1249
  North American
    geographical distribution of, 1242–1243

Plaque(s)
  pigmented
    canine PVs and, 1187–1188

Protein(s)
  acute-phase
    in FCoV diagnosis, 1146–1149
  serum
    in FCoV diagnosis, 1146

PVs. See Papillomavirus(es) (PVs)

R

Reproductive disorders
  canine
    CHV and, 1098–1100

Respiratory disorders
  canine
    CHV and, 1100–1103

Reverse transcriptase polymerase chain reaction (RT-PCR)
  in FCoV diagnosis, 1150–1151

RT-PCR. See Reverse transcriptase polymerase chain reaction (RT-PCR)

S

Salmonellosis
  in companion parrots
    transmission to dogs and cats, 1264–1265

Sanitation
  in FRDC prevention, 1284

Serology
  in FCoV diagnosis, 1149–1150

Serum proteins
  in FCoV diagnosis, 1146

Shelter cats
  immunity and stress in, 1144
Snake(s)
  venomous
    in North America, 1239–1242
Snake envenomation
  North American
    in dogs and cats, **1239–1259**
      clinical signs of, 1241, 1243
      complications of, 1256
      diagnostic testing related to, 1250–1252
      differential diagnoses of, 1249
    elapid envenomation
      clinical signs of, 1243–1244
      emergency field treatment/first aid for, 1249–1250
      in-hospital treatment for, 1252–1256
      pit viper envenomation, 1244–1249
      toxic effects of, 1241, 1243
Stress
  in shelter cats, 1144
Stress reduction
  in FRDC prevention, 1283

U
Urban wildlife
  domestic dogs from
    CDV in, **1069–1086**. See also Canine distemper virus (CDV), in domestic dogs from urban wildlife

V
Vaccination
  in FCoV prevention, 1155
  in FRDC prevention, 1282–1283

Y
Yersinia pseudotuberculosis
  companion parrot diseases related to
    transmission to dogs and cats, 1265

Z
Zoonosis
  canine brucellosis and, 1218